RecruitingNCT06500403

Non-invasive Tools for PSVD Diagnosis

Noninvasive Tools for the Diagnosis of Porto-sinusoidal Vascular Disease: a Single-center, Prospective, Cohort Study

Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

1,000 participants

Start Date

Feb 28, 2024

Study Type

OBSERVATIONAL

Conditions

Non-Cirrhotic Portal Hypertension Porto-Sinusoidal Vascular Diseases

Summary

Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at non-invasive (no surgery) tools to diagnose a liver condition called porto-sinusoidal vascular disease (PSVD), which is a form of liver blood vessel damage sometimes seen after platinum-based chemotherapy for cancer. **You may be eligible if...** - You have received platinum-based chemotherapy (such as cisplatin or oxaliplatin) for a solid organ tumor - You are between 18 and 80 years old - You are willing to sign informed consent **You may NOT be eligible if...** - Your liver biopsy shows cirrhosis (scarring of the liver) - You have had a liver transplant - You have liver cancer that exceeds certain size criteria (Milan criteria) - You have severe heart, kidney, or lung failure - You are pregnant or breastfeeding - Your medical records are significantly incomplete Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.